ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neisseria meningitidis Infections Drug Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-19W7196
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Neisseria meningitidis Infections Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Neisseria meningitidis Infections Drug Market Research Report 2025

Code: QYRE-Auto-19W7196
Report
September 2025
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
China National Pharmaceutical Group Corp
GlaxoSmithKline PLC
Griffith University
ImmunoBiology
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Pfizer Inc
Sanofi Pasteur SA.
Serum Institute of India Ltd
Wellstat Vaccines LLC

Neisseria meningitidis Infections Drug Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neisseria meningitidis Infections Drug Market

Neisseria meningitidis Infections Drug Market

The global market for Neisseria meningitidis Infections Drug was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neisseria meningitidis Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neisseria meningitidis Infections Drug.
The Neisseria meningitidis Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neisseria meningitidis Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neisseria meningitidis Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neisseria meningitidis Infections Drug Market Report

Report Metric Details
Report Name Neisseria meningitidis Infections Drug Market
CAGR 5%
Segment by Type
  • MGBBP-3
  • NCL-195
  • TP-10
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, China National Pharmaceutical Group Corp, GlaxoSmithKline Plc, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Wellstat Vaccines LLC
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neisseria meningitidis Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neisseria meningitidis Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Neisseria meningitidis Infections Drug Market report?

Ans: The main players in the Neisseria meningitidis Infections Drug Market are Beijing Minhai Biotechnology Co Ltd, Biological E Ltd, China National Pharmaceutical Group Corp, GlaxoSmithKline Plc, Griffith University, ImmunoBiology Ltd, JN-International Medical Corp, MGB Biopharma Ltd, Panacea Biotec Ltd, Pfizer Inc, Sanofi Pasteur SA, Serum Institute of India Ltd, Wellstat Vaccines LLC

What are the Application segmentation covered in the Neisseria meningitidis Infections Drug Market report?

Ans: The Applications covered in the Neisseria meningitidis Infections Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Neisseria meningitidis Infections Drug Market report?

Ans: The Types covered in the Neisseria meningitidis Infections Drug Market report are MGBBP-3, NCL-195, TP-10, Others

Recommended Reports

Infectious Disease Drugs

Vaccines & Immunization

Diagnostics & Testing

1 Neisseria meningitidis Infections Drug Market Overview
1.1 Product Definition
1.2 Neisseria meningitidis Infections Drug by Type
1.2.1 Global Neisseria meningitidis Infections Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 MGBBP-3
1.2.3 NCL-195
1.2.4 TP-10
1.2.5 Others
1.3 Neisseria meningitidis Infections Drug by Application
1.3.1 Global Neisseria meningitidis Infections Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Neisseria meningitidis Infections Drug Market Size Estimates and Forecasts
1.4.1 Global Neisseria meningitidis Infections Drug Revenue 2020-2031
1.4.2 Global Neisseria meningitidis Infections Drug Sales 2020-2031
1.4.3 Global Neisseria meningitidis Infections Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neisseria meningitidis Infections Drug Market Competition by Manufacturers
2.1 Global Neisseria meningitidis Infections Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neisseria meningitidis Infections Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neisseria meningitidis Infections Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neisseria meningitidis Infections Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Product Type & Application
2.7 Global Key Manufacturers of Neisseria meningitidis Infections Drug, Date of Enter into This Industry
2.8 Global Neisseria meningitidis Infections Drug Market Competitive Situation and Trends
2.8.1 Global Neisseria meningitidis Infections Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neisseria meningitidis Infections Drug Players Market Share by Revenue
2.8.3 Global Neisseria meningitidis Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neisseria meningitidis Infections Drug Market Scenario by Region
3.1 Global Neisseria meningitidis Infections Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neisseria meningitidis Infections Drug Sales by Region: 2020-2031
3.2.1 Global Neisseria meningitidis Infections Drug Sales by Region: 2020-2025
3.2.2 Global Neisseria meningitidis Infections Drug Sales by Region: 2026-2031
3.3 Global Neisseria meningitidis Infections Drug Revenue by Region: 2020-2031
3.3.1 Global Neisseria meningitidis Infections Drug Revenue by Region: 2020-2025
3.3.2 Global Neisseria meningitidis Infections Drug Revenue by Region: 2026-2031
3.4 North America Neisseria meningitidis Infections Drug Market Facts & Figures by Country
3.4.1 North America Neisseria meningitidis Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neisseria meningitidis Infections Drug Sales by Country (2020-2031)
3.4.3 North America Neisseria meningitidis Infections Drug Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neisseria meningitidis Infections Drug Market Facts & Figures by Country
3.5.1 Europe Neisseria meningitidis Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neisseria meningitidis Infections Drug Sales by Country (2020-2031)
3.5.3 Europe Neisseria meningitidis Infections Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neisseria meningitidis Infections Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Neisseria meningitidis Infections Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neisseria meningitidis Infections Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Neisseria meningitidis Infections Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neisseria meningitidis Infections Drug Market Facts & Figures by Country
3.7.1 Latin America Neisseria meningitidis Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neisseria meningitidis Infections Drug Sales by Country (2020-2031)
3.7.3 Latin America Neisseria meningitidis Infections Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neisseria meningitidis Infections Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Neisseria meningitidis Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neisseria meningitidis Infections Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neisseria meningitidis Infections Drug Sales by Type (2020-2031)
4.1.1 Global Neisseria meningitidis Infections Drug Sales by Type (2020-2025)
4.1.2 Global Neisseria meningitidis Infections Drug Sales by Type (2026-2031)
4.1.3 Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2020-2031)
4.2 Global Neisseria meningitidis Infections Drug Revenue by Type (2020-2031)
4.2.1 Global Neisseria meningitidis Infections Drug Revenue by Type (2020-2025)
4.2.2 Global Neisseria meningitidis Infections Drug Revenue by Type (2026-2031)
4.2.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2020-2031)
4.3 Global Neisseria meningitidis Infections Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neisseria meningitidis Infections Drug Sales by Application (2020-2031)
5.1.1 Global Neisseria meningitidis Infections Drug Sales by Application (2020-2025)
5.1.2 Global Neisseria meningitidis Infections Drug Sales by Application (2026-2031)
5.1.3 Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2020-2031)
5.2 Global Neisseria meningitidis Infections Drug Revenue by Application (2020-2031)
5.2.1 Global Neisseria meningitidis Infections Drug Revenue by Application (2020-2025)
5.2.2 Global Neisseria meningitidis Infections Drug Revenue by Application (2026-2031)
5.2.3 Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2020-2031)
5.3 Global Neisseria meningitidis Infections Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Beijing Minhai Biotechnology Co Ltd
6.1.1 Beijing Minhai Biotechnology Co Ltd Company Information
6.1.2 Beijing Minhai Biotechnology Co Ltd Description and Business Overview
6.1.3 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.1.5 Beijing Minhai Biotechnology Co Ltd Recent Developments/Updates
6.2 Biological E Ltd
6.2.1 Biological E Ltd Company Information
6.2.2 Biological E Ltd Description and Business Overview
6.2.3 Biological E Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Biological E Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.2.5 Biological E Ltd Recent Developments/Updates
6.3 China National Pharmaceutical Group Corp
6.3.1 China National Pharmaceutical Group Corp Company Information
6.3.2 China National Pharmaceutical Group Corp Description and Business Overview
6.3.3 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product Portfolio
6.3.5 China National Pharmaceutical Group Corp Recent Developments/Updates
6.4 GlaxoSmithKline Plc
6.4.1 GlaxoSmithKline Plc Company Information
6.4.2 GlaxoSmithKline Plc Description and Business Overview
6.4.3 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product Portfolio
6.4.5 GlaxoSmithKline Plc Recent Developments/Updates
6.5 Griffith University
6.5.1 Griffith University Company Information
6.5.2 Griffith University Description and Business Overview
6.5.3 Griffith University Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Griffith University Neisseria meningitidis Infections Drug Product Portfolio
6.5.5 Griffith University Recent Developments/Updates
6.6 ImmunoBiology Ltd
6.6.1 ImmunoBiology Ltd Company Information
6.6.2 ImmunoBiology Ltd Description and Business Overview
6.6.3 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.6.5 ImmunoBiology Ltd Recent Developments/Updates
6.7 JN-International Medical Corp
6.7.1 JN-International Medical Corp Company Information
6.7.2 JN-International Medical Corp Description and Business Overview
6.7.3 JN-International Medical Corp Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 JN-International Medical Corp Neisseria meningitidis Infections Drug Product Portfolio
6.7.5 JN-International Medical Corp Recent Developments/Updates
6.8 MGB Biopharma Ltd
6.8.1 MGB Biopharma Ltd Company Information
6.8.2 MGB Biopharma Ltd Description and Business Overview
6.8.3 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.8.5 MGB Biopharma Ltd Recent Developments/Updates
6.9 Panacea Biotec Ltd
6.9.1 Panacea Biotec Ltd Company Information
6.9.2 Panacea Biotec Ltd Description and Business Overview
6.9.3 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.9.5 Panacea Biotec Ltd Recent Developments/Updates
6.10 Pfizer Inc
6.10.1 Pfizer Inc Company Information
6.10.2 Pfizer Inc Description and Business Overview
6.10.3 Pfizer Inc Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Pfizer Inc Neisseria meningitidis Infections Drug Product Portfolio
6.10.5 Pfizer Inc Recent Developments/Updates
6.11 Sanofi Pasteur SA
6.11.1 Sanofi Pasteur SA Company Information
6.11.2 Sanofi Pasteur SA Description and Business Overview
6.11.3 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product Portfolio
6.11.5 Sanofi Pasteur SA Recent Developments/Updates
6.12 Serum Institute of India Ltd
6.12.1 Serum Institute of India Ltd Company Information
6.12.2 Serum Institute of India Ltd Description and Business Overview
6.12.3 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product Portfolio
6.12.5 Serum Institute of India Ltd Recent Developments/Updates
6.13 Wellstat Vaccines LLC
6.13.1 Wellstat Vaccines LLC Company Information
6.13.2 Wellstat Vaccines LLC Description and Business Overview
6.13.3 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product Portfolio
6.13.5 Wellstat Vaccines LLC Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neisseria meningitidis Infections Drug Industry Chain Analysis
7.2 Neisseria meningitidis Infections Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neisseria meningitidis Infections Drug Production Mode & Process Analysis
7.4 Neisseria meningitidis Infections Drug Sales and Marketing
7.4.1 Neisseria meningitidis Infections Drug Sales Channels
7.4.2 Neisseria meningitidis Infections Drug Distributors
7.5 Neisseria meningitidis Infections Drug Customer Analysis
8 Neisseria meningitidis Infections Drug Market Dynamics
8.1 Neisseria meningitidis Infections Drug Industry Trends
8.2 Neisseria meningitidis Infections Drug Market Drivers
8.3 Neisseria meningitidis Infections Drug Market Challenges
8.4 Neisseria meningitidis Infections Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Beijing Minhai Biotechnology Co Ltd
Biological E Ltd
China National Pharmaceutical Group Corp
GlaxoSmithKline PLC
Griffith University
ImmunoBiology
JN-International Medical Corp
MGB Biopharma Ltd
Panacea Biotec Ltd
Pfizer Inc
Sanofi Pasteur SA.
Serum Institute of India Ltd
Wellstat Vaccines LLC
List of Tables
 Table 1. Global Neisseria meningitidis Infections Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neisseria meningitidis Infections Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neisseria meningitidis Infections Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neisseria meningitidis Infections Drug Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Neisseria meningitidis Infections Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neisseria meningitidis Infections Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neisseria meningitidis Infections Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neisseria meningitidis Infections Drug Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neisseria meningitidis Infections Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Neisseria meningitidis Infections Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neisseria meningitidis Infections Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neisseria meningitidis Infections Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neisseria meningitidis Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neisseria meningitidis Infections Drug Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Neisseria meningitidis Infections Drug Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Neisseria meningitidis Infections Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Neisseria meningitidis Infections Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Neisseria meningitidis Infections Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neisseria meningitidis Infections Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Neisseria meningitidis Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neisseria meningitidis Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Neisseria meningitidis Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neisseria meningitidis Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neisseria meningitidis Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neisseria meningitidis Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Neisseria meningitidis Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neisseria meningitidis Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neisseria meningitidis Infections Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neisseria meningitidis Infections Drug Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Neisseria meningitidis Infections Drug Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Neisseria meningitidis Infections Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neisseria meningitidis Infections Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neisseria meningitidis Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neisseria meningitidis Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Neisseria meningitidis Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neisseria meningitidis Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neisseria meningitidis Infections Drug Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Neisseria meningitidis Infections Drug Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neisseria meningitidis Infections Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neisseria meningitidis Infections Drug Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Neisseria meningitidis Infections Drug Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Neisseria meningitidis Infections Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Neisseria meningitidis Infections Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neisseria meningitidis Infections Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Neisseria meningitidis Infections Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Neisseria meningitidis Infections Drug Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Neisseria meningitidis Infections Drug Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Neisseria meningitidis Infections Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Neisseria meningitidis Infections Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neisseria meningitidis Infections Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Neisseria meningitidis Infections Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Application (2026-2031)
 Table 70. Beijing Minhai Biotechnology Co Ltd Company Information
 Table 71. Beijing Minhai Biotechnology Co Ltd Description and Business Overview
 Table 72. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. Beijing Minhai Biotechnology Co Ltd Neisseria meningitidis Infections Drug Product
 Table 74. Beijing Minhai Biotechnology Co Ltd Recent Developments/Updates
 Table 75. Biological E Ltd Company Information
 Table 76. Biological E Ltd Description and Business Overview
 Table 77. Biological E Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. Biological E Ltd Neisseria meningitidis Infections Drug Product
 Table 79. Biological E Ltd Recent Developments/Updates
 Table 80. China National Pharmaceutical Group Corp Company Information
 Table 81. China National Pharmaceutical Group Corp Description and Business Overview
 Table 82. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. China National Pharmaceutical Group Corp Neisseria meningitidis Infections Drug Product
 Table 84. China National Pharmaceutical Group Corp Recent Developments/Updates
 Table 85. GlaxoSmithKline Plc Company Information
 Table 86. GlaxoSmithKline Plc Description and Business Overview
 Table 87. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. GlaxoSmithKline Plc Neisseria meningitidis Infections Drug Product
 Table 89. GlaxoSmithKline Plc Recent Developments/Updates
 Table 90. Griffith University Company Information
 Table 91. Griffith University Description and Business Overview
 Table 92. Griffith University Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Griffith University Neisseria meningitidis Infections Drug Product
 Table 94. Griffith University Recent Developments/Updates
 Table 95. ImmunoBiology Ltd Company Information
 Table 96. ImmunoBiology Ltd Description and Business Overview
 Table 97. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 98. ImmunoBiology Ltd Neisseria meningitidis Infections Drug Product
 Table 99. ImmunoBiology Ltd Recent Developments/Updates
 Table 100. JN-International Medical Corp Company Information
 Table 101. JN-International Medical Corp Description and Business Overview
 Table 102. JN-International Medical Corp Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 103. JN-International Medical Corp Neisseria meningitidis Infections Drug Product
 Table 104. JN-International Medical Corp Recent Developments/Updates
 Table 105. MGB Biopharma Ltd Company Information
 Table 106. MGB Biopharma Ltd Description and Business Overview
 Table 107. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 108. MGB Biopharma Ltd Neisseria meningitidis Infections Drug Product
 Table 109. MGB Biopharma Ltd Recent Developments/Updates
 Table 110. Panacea Biotec Ltd Company Information
 Table 111. Panacea Biotec Ltd Description and Business Overview
 Table 112. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 113. Panacea Biotec Ltd Neisseria meningitidis Infections Drug Product
 Table 114. Panacea Biotec Ltd Recent Developments/Updates
 Table 115. Pfizer Inc Company Information
 Table 116. Pfizer Inc Description and Business Overview
 Table 117. Pfizer Inc Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 118. Pfizer Inc Neisseria meningitidis Infections Drug Product
 Table 119. Pfizer Inc Recent Developments/Updates
 Table 120. Sanofi Pasteur SA Company Information
 Table 121. Sanofi Pasteur SA Description and Business Overview
 Table 122. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 123. Sanofi Pasteur SA Neisseria meningitidis Infections Drug Product
 Table 124. Sanofi Pasteur SA Recent Developments/Updates
 Table 125. Serum Institute of India Ltd Company Information
 Table 126. Serum Institute of India Ltd Description and Business Overview
 Table 127. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 128. Serum Institute of India Ltd Neisseria meningitidis Infections Drug Product
 Table 129. Serum Institute of India Ltd Recent Developments/Updates
 Table 130. Wellstat Vaccines LLC Company Information
 Table 131. Wellstat Vaccines LLC Description and Business Overview
 Table 132. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 133. Wellstat Vaccines LLC Neisseria meningitidis Infections Drug Product
 Table 134. Wellstat Vaccines LLC Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Neisseria meningitidis Infections Drug Distributors List
 Table 138. Neisseria meningitidis Infections Drug Customers List
 Table 139. Neisseria meningitidis Infections Drug Market Trends
 Table 140. Neisseria meningitidis Infections Drug Market Drivers
 Table 141. Neisseria meningitidis Infections Drug Market Challenges
 Table 142. Neisseria meningitidis Infections Drug Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neisseria meningitidis Infections Drug
 Figure 2. Global Neisseria meningitidis Infections Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neisseria meningitidis Infections Drug Market Share by Type: 2024 & 2031
 Figure 4. MGBBP-3 Product Picture
 Figure 5. NCL-195 Product Picture
 Figure 6. TP-10 Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Neisseria meningitidis Infections Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Neisseria meningitidis Infections Drug Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Neisseria meningitidis Infections Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Neisseria meningitidis Infections Drug Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Neisseria meningitidis Infections Drug Sales (2020-2031) & (K Pcs)
 Figure 16. Global Neisseria meningitidis Infections Drug Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Neisseria meningitidis Infections Drug Report Years Considered
 Figure 18. Neisseria meningitidis Infections Drug Sales Share by Manufacturers in 2024
 Figure 19. Global Neisseria meningitidis Infections Drug Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Neisseria meningitidis Infections Drug Players: Market Share by Revenue in Neisseria meningitidis Infections Drug in 2024
 Figure 21. Neisseria meningitidis Infections Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Neisseria meningitidis Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Neisseria meningitidis Infections Drug Sales Market Share by Country (2020-2031)
 Figure 24. North America Neisseria meningitidis Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Neisseria meningitidis Infections Drug Sales Market Share by Country (2020-2031)
 Figure 28. Europe Neisseria meningitidis Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Neisseria meningitidis Infections Drug Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Neisseria meningitidis Infections Drug Revenue Market Share by Region (2020-2031)
 Figure 36. China Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Neisseria meningitidis Infections Drug Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Neisseria meningitidis Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Neisseria meningitidis Infections Drug Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Neisseria meningitidis Infections Drug Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Neisseria meningitidis Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Neisseria meningitidis Infections Drug by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Neisseria meningitidis Infections Drug by Type (2020-2031)
 Figure 58. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Neisseria meningitidis Infections Drug by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Neisseria meningitidis Infections Drug by Application (2020-2031)
 Figure 61. Global Neisseria meningitidis Infections Drug Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Neisseria meningitidis Infections Drug Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Meningitis Vaccine Market Research Report 2025
Meningococcal Vaccination Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prevent Meningitis Vaccine Market Research Report 2025
Global Meningioma Drug Market Research Report 2024
Global Group ACYW135 Meningococcal Polysaccharide Vaccine Market Research Report 2025
Global Klebsiella Pneumoniae Infection Drug Market Research Report 2024
Global Anti infectious Disease Drugs Market Research Report 2025
Global Anti Infectives Market Research Report 2025
Global Meningococcal Infections Treatment Market Research Report 2024
Global Middle Ear Infection Treatment Market Research Report 2025
Global Aquaculture Bacterial Diagnosis Market Research Report 2025
Global Meniere Disease Drugs Market Research Report 2024
Global Sexually Transmitted Diseases Drug Market Research Report 2025
Global Feed Anticoccidials Market Insights Forecast to 2030
Global Rhinovirus Infections Drug Market Research Report 2024
Global Respiratory Infection Diagnostic Market Research Report 2024
Global Intracranial Treatment Drug Market Research Report 2025
Global Inhaled Anti Infectives Market Research Report 2025
Infectious Enteritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antimicrobial Susceptibility Testing Product Market
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions